| Cancer Treatment:
The Critical Factors
Updated: 07/29/2004
References
Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin augments sulindac-induced
apoptosis in colon cancer cells and potentiates chemopreventive effects
of sulindac. Gastroenterology. 1999 Oct;117(4):838-47.
Anon. Ras oncogenes: ras oncogenes in human cancer: a review 1990. Cancer
Res. 1990;50(4):1352.
Asamoto M, Ota T, Toriyama-Baba H, et al. Mammary carcinomas induced in
human c-Ha-ras proto-oncogene transgenic rats are estrogen-independent,
but responsive to d-limonene treatment. Jpn J Cancer Res. 2002 Jan;93(1):32-5.
Bartram CR. Mutations in ras genes in myelocytic leukemias and myelodysplastic
syndromes. Blood Cells. 1988;14(2-3):533-8.
Bland J. Farnesyl transferase inhibitors.2001;October 17-21, 2001.
Bonnel RA, Villalba ML, Karwoski CB, et al. Aseptic meningitis associated
with rofecoxib. Arch Intern Med. 2002 Mar 25;162(6):713-5.
Brody JE. Aspirin linked to aid in colon cancer fight. New York Times.
1991;141(48, 812):A12.
Cafagna D, Ponte E. [Pulmonary embolism of paraneoplastic origin]. Minerva
Med. 1997 Dec;88(12):523-30.
Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor
for survival in patients with cancer: a systemic, quantitative review.
Cancer. 2001 Jun 15;91(12):2214-21.
Cazzola M. Mechanisms of anaemia in patients with malignancy: implications
for the clinical use of recombinant human erythropoietin. Med Oncol. 2000
Nov;17 Suppl 1:S11-S16.
Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation
with warfarin and of alternating chemotherapy in extensive small-cell
lung cancer by the Cancer and Leukemia Group B. J Clin Oncol. 1989 Aug;7(8):993-1002.
Chung JY, Huang C, Meng X, et al. Inhibition of activator protein 1 activity
and cell growth by purified green tea and black tea polyphenols in H-ras-transformed
cells: structure-activity relationship and mechanisms involved. Cancer
Res. 1999 Sep 15;59(18):4610-7.
Collett ED, Davidson LA, Fan YY, et al. n-6 and n-3 polyunsaturated fatty
acids differentially modulate oncogenic Ras activation in colonocytes.
Am J Physiol Cell Physiol. 2001 May;280(5):C1066-C1075.
Conti F, Vici P. [Vinorelbin in the treatment of breast cancer: current
status and prospectives for the future]. Clin Ter. 1998 Jan;149(921):61-74.
Cosgrove RH, Zacharski LR, Racine E, et al. Improved cancer mortality
with low-molecular-weight heparin treatment: a review of the evidence.
Semin Thromb Hemost. 2002 Feb;28(1):79-87.
De Placido S, Lauria R, Perrone F, et al. Vinorelbine + mitomycin C as
second-line treatment of metastatic breast cancer: a two-stage phase 2
study. Oncology. 2000;58(1):8-14.
Dunst J, Pigorsch S, Hansgen G, et al. Low hemoglobin is associated with
increased serum levels of vascular endothelial growth factor (VEGF) in
cancer patients. Does anemia stimulate angiogenesis? Strahlenther Onkol.
1999 Mar;175(3):93-6.
Duursma AM, Agami R. Ras interference as cancer therapy. Semin Cancer
Biol. 2003 Aug;13(4):267-73.
Feramisco JR, Clark R, Wong G, et al. Transient reversion of ras oncogene-induced
cell transformation by antibodies specific for amino acid 12 of ras protein.
Nature. 1985 Apr 18;314(6012):639-42.
Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated
polysaccharides. Adv Exp Med Biol. 1992;313:355-64.
Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol.
1992 Apr;3(2):65-71.
Frasci G, D'Aiuto G, Comella P, et al. A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic
acid triplet combination in anthracycline- and taxane-refractory breast
cancer patients. Oncology. 2002;62(1):25-32.
Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis.
Cancer Metastasis Rev. 2000;19(1-2):19-27.
Gibbs JB, Kohl NE, Koblan KS, et al. Farnesyltransferase inhibitors and
anti-Ras therapy. Breast Cancer Res Treat. 1996;38(1):75-83.
Gralla R, Harper P, Johnson S, et al. Vinorelbine (Navelbine) in the treatment
of non-small-cell lung cancer: studies with single-agent therapy and in
combination with cisplatin. Ann Oncol. 1999;10 Suppl 5:S41-S45.
Gralla R, Harper P, Johnson S, et al. Vinorelbine (navelbine) in the treatment
of non-small-cell lung cancer: recent developments in combination chemotherapy
and radiotherapy. Ann Oncol. 1999;10 Suppl 5:S47-S51.
Hanjani P, Nolte S, Shahin MS. Phase II evaluation of 3-day topotecan
with cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecol
Oncol. 2002 May;85(2):278-84.
Harper P. ICON 2 and ICON 3 data in previously untreated ovarian cancer:
results to date. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15.
Herrera J, Nava M, Romero F, et al. Melatonin prevents oxidative stress
resulting from iron and erythropoietin administration. Am J Kidney Dis.
2001 Apr;37(4):750-7.
Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin
on RAS processing. J Biol Chem. 1995 Jul 21;270(29):17508-12.
Knorr J. Aspirin: the multi-purpose compound not just for headaches anymore.
Life Extension Magazine 2000 Feb. 2000;Life Extension Magazine 2000 Feb6(2):50.
Kohli M, Fink LM, Spencer HJ, et al. Advanced prostate cancer activates
coagulation: a controlled study of activation markers of coagulation in
ambulatory patients with localized and advanced prostate cancer. Blood
Coagul Fibrinolysis. 2002 Jan;13(1):1-5.
Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment
increases survival in small cell lung cancer. "Petites Cellules"
Group. Cancer. 1994 Jul 1;74(1):38-45.
Lu X, Xu T, Qian J. [An application value of detecting K-ras and p53 gene
mutation in the stool and pure pancreatic juice for diagnosis of early
pancreatic cancer]. Zhonghua Yi Xue Za Zhi. 2001 Sep 10;81(17):1050-3.
McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin
compared with paclitaxel and cisplatin in patients with stage III and
stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1-6.
Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular
diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a
review. Cancer Detect Prev. 2000;24(1):1-12.
Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory
drugs and cancer risks. J Environ Pathol Toxicol Oncol. 2002;21(2):193-201.
Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Expert
Rev Anticancer Ther. 2002 Apr;2(2):227-33.
Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated
with selective COX-2 inhibitors. JAMA. 2001 Aug 22;286(8):954-9.
Nagourney RA. Proceedings of the American Society of Clinical Oncology.1995.
Nagourney RA, Link JS, Blitzer JB, et al. Gemcitabine plus cisplatin repeating
doublet therapy in previously treated, relapsed breast cancer patients.
J Clin Oncol. 2000 Jun;18(11):2245-9.
Nakatsugi S, Fukutake M, Takahashi M, et al. Suppression of intestinal
polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor,
in Min mice. Jpn J Cancer Res. 1997 Dec;88(12):1117-20.
Newmark T. Beyond Aspirin.2000.
NIH/NCI. Angiogenesis Inhibitors in Cancer Research. NIH/NCI Angiogenesis
Inhibitors in Cancer Research 1998 Jul 7 Bethesda, MD: National Cancer
Institute (Http://Www Slip Net/~Mcdavis/Database/Angio163 Htm).1998;Jul
7
Oliff A. Therapies of the Future: New Molecular Targets for Cancer Therapy.1996
Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Semin Oncol. 2000 Apr;27(2 Suppl 3):24-9.
Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin
Urol Oncol. 2002 Aug;20(3 Suppl 1):31-5.
Reddy BS, Rao CV. Colon cancer: a role for cyclo-oxygenase-2-specific
nonsteroidal anti-inflammatory drugs. Drugs Aging. 2000 May;16(5):329-34.
Samuels AJBHRSSB. Increased alpha 1 antitrypsin, decreased systemic fibrinolysis,
hypercoaguable state and increased fibrin split products in patients with
lung cancer. Proc Am Soc Clin Oncol. 1975;(16):238.
Sears B. A Dietary Road Map.1995.
Shammas NW, Moss AJ, Sullebarger JT, et al. Acquired coronary angiogenesis
after myocardial infarction. Cardiology. 1993;83(3):212-6.
Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between
cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999 Oct 6;282(13):1254-7.
Singh A, Purohit A, Hejaz HA, et al. Inhibition of deoxyglucose uptake
in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate.
Mol Cell Endocrinol. 2000 Feb 25;160(1-2):61-6.
Spivak JL. Cancer-related anemia: its causes and characteristics. Semin
Oncol. 1994 Apr;21(2 Suppl 3):3-8.
Suh DY. Understanding angiogenesis and its clinical applications. Ann
Clin Lab Sci. 2000 Jul;30(3):227-38.
Tew KD, Woodworth A, Stearns ME. Relationship of glutathione depletion
and inhibition of glutathione-S-transferase activity to the antimitotic
properties of estramustine. Cancer Treat Rep. 1986 Jun;70(6):715-20.
Tew KD, Stearns ME. Hormone-independent, non-alkylating mechanism of cytotoxicity
for estramustine. Urol Res. 1987;15(3):155-60.
Tew KD, Glusker JP, Hartley-Asp B, et al. Preclinical and clinical perspectives
on the use of estramustine as an antimitotic drug. Pharmacol Ther. 1992
Dec;56(3):323-39.
Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis
induced by colon cancer cells. Cell. 1998 May 29;93(5):705-16.
Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression
is up-regulated in human pancreatic cancer. Cancer Res. 1999 Mar 1;59(5):987-90.
Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related
to prostaglandin biosynthesis and angiogenesis in human gastric cancer.
Clin Cancer Res. 2000 Jan;6(1):135-8.
Vachtenheim J. Occurrence of ras mutations in human lung cancer. Minireview.
Neoplasma. 1997;44(3):145-9.
Vaziri ND, Oveisi F, Reyes GA, et al. Dysregulation of melatonin metabolism
in chronic renal insufficiency: role of erythropoietin-deficiency anemia.
Kidney Int. 1996 Aug;50(2):653-6.
von Tempelhoff GF, Harenberg J, Niemann F, et al. Effect of low molecular
weight heparin (Certoparin) versus unfractionated heparin on cancer survival
following breast and pelvic cancer surgery: A prospective randomized double-blind
trial. Int J Oncol. 2000 Apr;16(4):815-24.
Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression
in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition
of ras isoprenylation. Oncology. 2000 Sep;59(3):245-54.
Weisenthal LM, Kern DH. Prediction of drug resistance in cancer chemotherapy:
the Kern and DiSC assays. Oncology (Huntingt). 1991 Sep;5(9):93-103.
Wellness Directory of Minnesota.2002
Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation
on survival in carcinoma of the lung, colon, head and neck, and prostate.
Final report of VA Cooperative Study #75. Cancer. 1984 May 15;53(10):2046-52.
Zacharski LR. Small cell carcinoma of the lung: interaction with the blood
coagulation mechanism and treatment with anticoagulants. Onkologie. 1987
Aug;10(4):264-70.
Zacharski LR, Memoli VA, Rousseau SM, et al. Occurrence of blood coagulation
factors in situ in small cell carcinoma of the lung. Cancer. 1987 Dec
1;60(11):2675-81.
Zurborn KH, Bernsmeier R, Schamerowski F, et al. [Coagulation disorders
in tumors and hemoblastoses]. Onkologie. 1982 Aug;5(4):186-90. |